Author:
van Staveren M C,Jan Guchelaar H,van Kuilenburg A B P,Gelderblom H,Maring J G
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology,Genetics,Molecular Medicine
Reference74 articles.
1. Diasio RB, Harris BE . Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989; 16: 215–237.
2. Fleming RA, Milano G, Thyss A, Etienne MC, Renee N, Schneider M et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 1992; 52: 2899–2902.
3. Harris BE, Song R, Soong SJ, Diasio RB . Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990; 50: 197–201.
4. Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renee N et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994; 12: 2248–2253.
5. van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH . Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation. Int J Cancer 2002; 101: 253–258.
Cited by
72 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献